R. E. Broadberry
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
R. E. Broadberry has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
G. Garratty
American Red Cross Blood Services, Los Angeles, CA, USA
1 shared publicationI. Skidmore
International Blood Group Reference Laboratory, NBS, Bristol, UK, and
1 shared publicationJ. A. Kohler
Paediatric Oncology, Southampton University Hospitals NHS Trust, Southampton
1 shared publicationJ. Poole
International Blood Group Reference Laboratory, NBS, Bristol, UK, and
1 shared publicationS. V. Bevin
Paediatric Oncology, Southampton University Hospitals NHS Trust, Southampton
1 shared publicationS. Yates
Transfusion Department
1 shared publication
Latest Publications
- 1 February 2004
- Published by Wiley in Transfusion Medicine
- Vol. 14 (1) , 53-57
Tazobactam‐induced haemolytic anaemia, possibly caused by non‐immunological adsorption of IgG onto patient's red cells
Summary. A patient with pneumonia was treated with Tazocin (piperacillin/tazobactam). However, the expected haemoglobin (Hb) increment after transfusion was not achieved. Plasma bilirubin and lactate dehydrogenase were raised. The direct antiglobulin test (DAT) was positive (4+) for immunoglobulin G (IgG) only, but no RBC antibodies were demonstrable in the plasma or an eluate from the patient's RBCs. Drug‐induced haemolysis was suspected. After discontinuing Tazocin administration, Hb and bilirubin levels returned to expected values.The patient's plasma gave a positive (3+) indirect antiglobulin reaction only with RBCs pretreated with tazobactam. However, random patient plasmas also gave weak (± to 1+) reactions, indicating non‐immunological adsorption of IgG onto RBCs rather than specific anti‐tazobactam antibodies.Subsequently, plasma samples with varying IgG levels (0·8–89·7 g L−1) were tested against RBCs pretreated with tazobactam. The amount of plasma IgG non‐immunologically adsorbed onto the drug‐coated RBCs was found to correlate directly with the plasma IgG level. The patient had a high plasma IgG level (41·6 g L−1) which explains why the antiglobulin test was stronger with the patient's plasma than with random plasma samples.Previous reports (Garratty & Arndt, (1998) British Journal of Haematology, 100, 777–783; Arndt & Garratty (2000) Transfusion, 40, 29S) suggested that non‐immunological coating of RBCs with IgG may affect RBC survival; our results would support that suggestion. This is the first reported case of haemolytic anaemia associated with tazobactam.
- 1 February 2004
- Published by Wiley in Transfusion Medicine
- Vol. 14 (1) , 53-57
Tazobactam‐induced haemolytic anaemia, possibly caused by non‐immunological adsorption of IgG onto patient's red cells
Summary. A patient with pneumonia was treated with Tazocin (piperacillin/tazobactam). However, the expected haemoglobin (Hb) increment after transfusion was not achieved. Plasma bilirubin and lactate dehydrogenase were raised. The direct antiglobulin test (DAT) was positive (4+) for immunoglobulin G (IgG) only, but no RBC antibodies were demonstrable in the plasma or an eluate from the patient's RBCs. Drug‐induced haemolysis was suspected. After discontinuing Tazocin administration, Hb and bilirubin levels returned to expected values.The patient's plasma gave a positive (3+) indirect antiglobulin reaction only with RBCs pretreated with tazobactam. However, random patient plasmas also gave weak (± to 1+) reactions, indicating non‐immunological adsorption of IgG onto RBCs rather than specific anti‐tazobactam antibodies.Subsequently, plasma samples with varying IgG levels (0·8–89·7 g L−1) were tested against RBCs pretreated with tazobactam. The amount of plasma IgG non‐immunologically adsorbed onto the drug‐coated RBCs was found to correlate directly with the plasma IgG level. The patient had a high plasma IgG level (41·6 g L−1) which explains why the antiglobulin test was stronger with the patient's plasma than with random plasma samples.Previous reports (Garratty & Arndt, (1998) British Journal of Haematology, 100, 777–783; Arndt & Garratty (2000) Transfusion, 40, 29S) suggested that non‐immunological coating of RBCs with IgG may affect RBC survival; our results would support that suggestion. This is the first reported case of haemolytic anaemia associated with tazobactam.